Holen Sie sich die Stockscreener-App
1.54
5.48%
0.08
Vorhandelsmarkt:
1.58
0.04
+2.60%
Longeveron Inc Aktie (LGVN) Neueste Nachrichten
What makes Longeveron Inc. stock price move sharplyFree Exclusive Stock Market Insights - Newser
Why Longeveron Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser
How Longeveron Inc. stock performs during market volatilityFree Stock Market Group - Newser
Longeveron (LGVN) gets FDA nod to start Phase 2 laromestrocel trial | PLUG SEC FilingForm 424B7 - Stock Titan
Longeveron receives FDA approval for pediatric heart therapy IND By Investing.com - Investing.com South Africa
Longeveron®? Announces U.S. FDA Approval of IND Application for A Phase 2 Pivotal Registration Study Evaluating Laromestrocel as A Treatment of Pediatric Dilated Cardiomyopathy - MarketScreener
Longeveron® announces U.S. FDA approval of IND application - MarketScreener
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - The Manila Times
Longeveron stock soars after FDA approves IND for heart failure treatment By Investing.com - Investing.com South Africa
Longeveron stock soars after FDA approves IND for heart failure treatment - Investing.com
Longeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - Nasdaq
Breakthrough: FDA Fast-Tracks New Stem Cell Therapy for Fatal Children's Heart Condition - Stock Titan
LGVN: Treatment Approved for Phase 2 Trial - Research Tree
Longeveron (NASDAQ:LGVN) Shares Down 1.5% – What’s Next? - Defense World
Longeveron appoints Than Powell as chief business officer - Investing.com
Longeveron (LGVN) Appoints New Chief Business Officer to Lead Strategic Initiatives | LGVN Stock News - GuruFocus
Longeveron® Appoints Than Powell as Chief Business Officer - GlobeNewswire
Longeveron Appoints Than Powell as Chief Business Officer, Effective July 7, 2025 - MarketScreener
Longeveron completes enrollment in HLHS pediatric heart trial - Investing.com India
Breakthrough HLHS Treatment Clinical Trial Hits Major Milestone: Previous Phase Shows 100% Patient Survival - Stock Titan
Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy - CGTLive®
Transcript : Longeveron Inc.Shareholder/Analyst Call - MarketScreener
Jane Street Group LLC Acquires New Shares in Longeveron Inc. (NASDAQ:LGVN) - Defense World
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - The Manila Times
Longeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Nasdaq
Exclusive Look: Longeveron CEO Reveals Latest Neuro Therapy Developments at Major Healthcare Conference - Stock Titan
18,190 Shares in Longeveron Inc. (NASDAQ:LGVN) Bought by Northern Trust Corp - Defense World
Director’s Major Stock Sale Shakes Up Longeveron! - TipRanks
Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely - Yahoo Finance
Q2 Earnings Estimate for Longeveron Issued By HC Wainwright - Defense World
Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International Convention - Nasdaq
Longeveron® to Attend BIO International Convention 2025 - Yahoo Finance
Longeveron Advances First RMAT-Designated Cell Therapy for Alzheimer's Disease | LGVNR Stock News - Stock Titan
Is Palantir Stock a Buy at All-Time Highs? - The Globe and Mail
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient - GlobeNewswire
Longeveron Inc. Named Top 40 Semifinalist in XPRIZE Healthspan Competition for Stem Cell Therapy Evaluation in Alzheimer’s Disease and HLHS - Nasdaq
Longeveron (LGVN) Projected to Post Earnings on Tuesday - Defense World
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Longeveron Q1 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com India
Longeveron Reports Q1 2025 Progress and Financials - TipRanks
Earnings call transcript: Longeveron Reports Q1 2025 Results Amid Revenue Decline - Investing.com Canada
Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World
Longeveron Earnings Preview: Latest Updates on Cellular Therapy Pipeline Coming May 8 - Stock Titan
Longeveron Inc. to Report Q1 2025 Financial Results and Business Update on May 8 - Nasdaq
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - The Manila Times
Longeveron Re-approves Cash-to-Equity Program Strategy - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
Longeveron® Issues Letter to Shareholders Highlighting - GlobeNewswire
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):